|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Combined hazard ratios suggested that VEGF-C overexpression was not associated with poor prognosis of disease-free survival (HR [hazard ratio] = 0.80, 95 % CI [confidence interval]: 0.51-1.09), overall survival (OS) (HR = 1.08, 95 % CI: 0.37-1.78) in patients with breast cancer.
|
24078449 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, short interfering RNA-mediated knockdown of COUP-TFII in the breast carcinoma cell line MCF-7 decreased the level of vascular endothelial growth factor-C mRNA expression, which is a known inducer of lymphangiogenesis and lymph node metastasis.
|
19154418 |
2009 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results reveal that CCR7 and VEGF-C display a significant crosstalk and suggest a novel role of the CCL21/CCR7 chemokine axis in the promotion of breast cancer-induced lymphangiogenesis.
|
25744065 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
I demonstrate in this paper that chitin hydrolysate served as a strong inducer of VEGF-C synthesis by human breast cancer MDA-MB-231 cells, increasing the secretion of VEGF-C to the cell culture medium as much as by 10-fold in comparison with the basal production.
|
21029043 |
2011 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical studies of breast cancer tumour tissue have reported a relation between the increased expression of vascular endothelial growth factor-C (VEGF-C) and the risk of lymph node metastasis.
|
26104766 |
2015 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that co-expression of VEGF-C and Twist was associated with larger tumor size, higher numbers of lymph node involvement, D2-40-positive LVI, higher risk of distant metastasis, and worse DFS or OS in breast cancer patients.
|
30788837 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we address these questions employing in vitro studies with a COX-2-expressing and VEGF-C/D-producing murine breast cancer cell line C3L5 and a rat mesenteric (RM) LEC line and in vivo studies in nude mice.
|
28056899 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study highlights that VEGF-C siRNA in combination with ultrasound-mediated microbubble destruction (UMMD) could be a powerful, promising nonviral technology for breast cancer gene therapy.
|
23879170 |
2013 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VEGFC and VEGFR1 mRNA overexpression is of prognostic value, dependent on HER2 status, in patients with high-risk early breast cancer undergoing adjuvant treatment.
|
26124351 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Due to the small samples and insufficient date, further studies should be conducted to clarify the association between the overexpression of CXCR4 or C-Met or VEGF-C and the prognosis about breast cancer patients.
|
27214240 |
2016 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we silenced the expression of VEGF-C with the highly specific post-transcriptional suppression of RNA interference (RNAi) in human breast cancer MCF-7 cell line.
|
17938864 |
2008 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, a retrospective study found that higher circulating VEGF-C levels were associated with better survival in breast cancer patients.
|
29963266 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our meta-analysis demonstrated that LVD, VEGF-C and VEGF-D could predict poor prognosis in patients with breast cancer.
|
23054001 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
By the means of immunohistochemistry, COX-2, vascular endothelial growth factor-C (VEGF-C) and D2-40 were examined in the tissue samples of primary tumors from 94 patients underwent surgical resections for breast cancer from November 1998 to March 2002.Eighty-three patients were followed-up.
|
18509974 |
2008 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, there was no association between VEGF-C expression and the clinicopathological factors or prognosis of breast cancer patients.
|
15943035 |
2005 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
EMP1 expression decreased in breast cancer and correlated significantly with lymph node metastasis, clinic stage, histological grade, and poor overall survival, T stages, suggesting that EMP1 may play important roles as a negative regulator to breast cancer MCF-7 cell by regulating the expression of caspase 9 and VEGFC protein.
|
24402572 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The level of VEGF-C and VEGF-D expression was also significantly higher in breast carcinomas than in benign mammary lesions, P<0.01.
|
18512120 |
2008 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
STS and breast cancer VEGF-C expression was comparable and higher than normal tissue levels.
|
19351758 |
2009 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study suggested that PKM2 expression was correlated with VEGF-C expression, and combination of PKM2 and VEGF-C levels had the better prognostic significance in predicting the poor outcome of patients with breast cancer.
|
26339369 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate concentrations, diagnostic utility and power of VEGF-A, VEGF-C, VEGF-D and VEGFR-2 in comparison to CA15-3 in breast cancer (BC) patients.
|
30387014 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway.
|
12471041 |
2003 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis showed that the level of VEGF-C expression was significantly related with that of survivin in breast cancer tissues (p<0.05).
|
22607367 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro.
|
28364216 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer-derived vascular endothelial growth factor-C (VEGF-C) has been shown to enhance lymphangiogenesis in lymph nodes to accelerate cancer metastasis.
|
31390756 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular Endotelial Growth Factors C and D (VEGF-C and VEGF-D) are crucial regulators of lymphangiogenesis, a main event in the metastatic spread of breast cancer tumors.
|
27806339 |
2016 |